Ipratropium : interactions médicamenteuses

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Hypersensitivity to ipratropium bromide or other ATROVENT HFA components Hypersensitivity to atropine or any of its derivatives Hypersensitivity to ipratropium bromide or other ATROVENT HFA components ( 4 ) (notice Ipratropium, Contre-indications)

Hypersensitivity to ipratropium bromide or other ATROVENT HFA components Hypersensitivity to atropine or any of its derivatives Hypersensitivity to ipratropium bromide or other ATROVENT HFA components ( 4 ) (notice Ipratropium, Contre-indications)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

In patients in whom there is cause for arrest or delay in tablet passage through the gastrointestinal tract, such as those suffering from delayed gastric emptying, esophageal compression, intestinal obstruction or stricture, or those taking anticholinergic medication. (notice Citrate de potassium, Contre-indications)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Hypersensitivity to ipratropium bromide or other ATROVENT HFA components Hypersensitivity to atropine or any of its derivatives Hypersensitivity to ipratropium bromide or other ATROVENT HFA components ( 4 ) (notice Ipratropium, Contre-indications)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Hypersensitivity to ipratropium bromide or other ATROVENT HFA components Hypersensitivity to atropine or any of its derivatives Hypersensitivity to ipratropium bromide or other ATROVENT HFA components ( 4 ) (notice Ipratropium, Contre-indications)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Intervention Concomitant use of anticholinergic drugs with GVOKE VialDx is not recommended. (notice Glucagon, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, malignant hyperthermia, drug fever, serotonin syndrome, and primary central nervous system pathology. (notice Métoclopramide, Mises en garde et précautions)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Hypersensitivity to ipratropium bromide or other ATROVENT HFA components Hypersensitivity to atropine or any of its derivatives Hypersensitivity to ipratropium bromide or other ATROVENT HFA components ( 4 ) (notice Ipratropium, Contre-indications)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Quinidine is also contraindicated in patients who, like those with myasthenia gravis, might be adversely affected by an anticholinergic agent. (notice Quinidine, Contre-indications)

IF INITIATION OF AEROSOLIZED RIBAVIRIN FOR INHALATION SOLUTION, USP TREATMENT APPEARS TO PRODUCE SUDDEN DETERIORATION OF RESPIRATORY FUNCTION, TREATMENT SHOULD BE STOPPED AND REINSTITUTED ONLY WITH EXTREME CAUTION, CONTINUOUS MONITORING AND CONSIDERATION OF CONCOMITANT ADMINISTRATION OF BRONCHODILATORS (SEE WARNINGS ). (notice Ribavirine, Mise en garde encadrée)

Concomitant use with metoclopramide, beta-blockers, or cholinomimetic and anticholinergic drugs is not recommended ( 7.1 , 7.2 , 7.3 ) (notice Rivastigmine, Interactions médicamenteuses)

Treatment of Acute Bronchospasm DALIRESP is not a bronchodilator and should not be used for the relief of acute bronchospasm. (notice Roflumilast, Mises en garde et précautions)

Other short-acting sympathomimetic aerosol bronchodilators should not be used concomitantly with albuterol. (notice Salbutamol, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

…(HR) b or Serotonin Syndrome (SS) c ] Agents with blood pressure-reducing effects Use with caution d Hypotension e Non-selective H1 receptor antagonists Contraindicated a Increased anticholinergic effects Beta-adrenergic blockers (see also agents or procedures with blood pressure-reducing effects) Use with the caution d More pronounced bradycardia, postural hypotension… (notice Tranylcypromine, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs ( 7.1 ) (notice Ipratropium, Interactions médicamenteuses)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (notice Aripiprazole, Mises en garde et précautions)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use SAPHRIS with caution in patient who may experience these conditions. (notice Asénapine, Mises en garde et précautions)

Since beta 1 selectivity is not absolute, the lowest possible dose of TENORMIN should be used with therapy initiated at 50 mg and a beta 2 -stimulating agent (bronchodilator) should be made available. (notice Aténolol, Mises en garde)

Since beta 1 -selectivity is not absolute, the lowest possible dose of atenolol and chlorthalidone should be used and a beta 2 -stimulating agent (bronchodilator) should be made available. (notice Aténolol et chlortalidone, Mises en garde)

Reduction of 15% or more in forced expiratory volume in 1 second (FEV 1 ) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON. (notice Aztréonam, Mises en garde et précautions)

Drugs that alter gastrointestinal motility: The bioavailability of thiazide-type diuretics may be increased by anticholinergic agents (e.g., atropine, biperiden), apparently due to a decrease in gastrointestinal motility and the stomach emptying rate. (notice Bénazépril et hydrochlorothiazide, Interactions médicamenteuses)

Since β 1 -selectivity is not absolute and is inversely related to dose, the lowest possible dose of betaxolol should be used (5 to 10 mg once daily) and a bronchodilator should be made available. (notice Bétaxolol, Mises en garde)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use REXULTI with caution in patients who may experience these conditions. (notice Brexpiprazole, Mises en garde et précautions)

Patients should be instructed to contact their physician immediately if episodes of asthma not responsive to their usual doses of bronchodilators occur during the course of treatment with PULMICORT FLEXHALER. (notice Budésonide, Mises en garde et précautions)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase the risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (notice Buprénorphine, Interactions médicamenteuses)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase the risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (notice Buprénorphine et naloxone, Interactions médicamenteuses)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (notice Butalbital, aspirine, caféine et codéine, Interactions médicamenteuses)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (notice Butalbital, paracétamol, caféine et codéine, Interactions médicamenteuses)

Increased Intraocular Pressure Carbamazepine has mild anticholinergic activity. (notice Carbamazépine, Mises en garde et précautions)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system (CNS) pathology. (notice Carbidopa, Mises en garde)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use VRAYLAR with caution in patient who may experience these conditions. (notice Cariprazine, Mises en garde et précautions)

Patients should be instructed to contact their physician immediately if episodes of asthma not responsive to their usual doses of bronchodilators occur during the course of treatment with ALVESCO. (notice Ciclésonide, Mises en garde et précautions)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (notice Codéine, Interactions médicamenteuses)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (notice Deutétrabénazine, Mises en garde et précautions)

The intravenous administration of anticholinergic agents (e.g., glycopyrrolate, atropine) should be considered to modify vagal tone. (notice Dexmédétomidine, Mises en garde et précautions)

Anticholinergic effects of quinidine: Monitor for worsening in myasthenia gravis and other sensitive conditions. (notice Dextrométhorphane et quinidine, Mises en garde et précautions)

Concomitant use of other drugs that cause dizziness, confusion, sedation, or somnolence such as CNS depressants may increase this effect (e.g., barbiturates, benzodiazepines, lithium, opioids, buspirone, scopolamine, antihistamines, tricyclic antidepressants, other anticholinergic agents, and muscle relaxants). (notice Dronabinol, Mises en garde et précautions)

Examples: alosetron, anticholinergics, opioids Table 3: Established and Other Potentially Clinically Relevant Interactions Affecting Drugs Co-Administered with VIBERZI OATP1B1 and BCRP Substrate Clinical Impact: VIBERZI may increase the exposure of co-administered OATP1B1 and BCRP substrates. (notice Éluxadoline, Interactions médicamenteuses)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (notice Fentanyl, Interactions médicamenteuses)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever and primary central nervous system (CNS) pathology. (notice Fluphénazine, Mises en garde)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever and primary central nervous system (CNS) pathology. (notice Halopéridol, Mises en garde)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (notice Hydrocodone, Interactions médicamenteuses)

Anticholinergic Drugs The concomitant use of anticholinergic drugs with hydrocodone bitartrate and homatropine methylbromide may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus [see Warnings and Precautions (5.9) ] . (notice Hydrocodone et homatropine, Interactions médicamenteuses)

Anticholinergics The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (notice Hydrocodone et ibuprofène, Interactions médicamenteuses)

Anticholinergic Drugs The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (notice Hydrocodone et paracétamol, Interactions médicamenteuses)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (notice Hydromorphone, Interactions médicamenteuses)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use FANAPT with caution in patients who may experience these conditions. (notice Ilopéridone, Mises en garde et précautions)

Because of its anticholinergic effects, XEOMIN should be used with caution in patients at risk of developing narrow angle glaucoma. (notice IncobotulinumtoxinA, Mises en garde et précautions)

Anticholinergic Drugs The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (notice Lévorphanol, Interactions médicamenteuses)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system (CNS) pathology. (notice Loxapine, Mises en garde)

Interrupt MARGENZA infusion in patients experiencing dyspnea or clinically significant hypotension and intervene with medical therapy which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators and oxygen. (notice Margétuximab, Mises en garde et précautions)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (notice Méthadone, Interactions médicamenteuses)

Bronchodilators, including beta 2 -agonists, should be readily available or administered concomitantly [see Dosage and Administration (2) ]. (notice Métoprolol, Mises en garde et précautions)

Because beta1-selectivity is not absolute, use the lowest possible dose of metoprolol tartrate and have bronchodilators (e.g., beta 2 -agonists) readily available or administered concomitantly . (notice Métoprolol et hydrochlorothiazide, Mises en garde et précautions)

• Urinary Retention in Patients With Bladder Outlet Obstruction and in Patients Taking Muscarinic Antagonist Drugs for Overactive Bladder : Administer with caution in these patients because of risk of urinary retention. (notice Mirabégron, Mises en garde et précautions)

In a 2-year double-blind study in 103 male and female asthma patients 18 to 50 years of age previously maintained on bronchodilator therapy (Baseline FEV 1 85%-88% predicted), treatment with mometasone furoate dry powder inhaler 200 mcg twice daily resulted in significant reductions in lumbar spine (LS) BMD at the end of the treatment period compared to placebo. (notice Mométasone, Mises en garde et précautions)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (notice Morphine, Interactions médicamenteuses)

Anticholinergic Drugs The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (notice Nalbuphine, Interactions médicamenteuses)

An anticholinergic agent, (e.g., atropine sulfate or glycopyrrolate) should be administered prior to Neostigmine Methylsulfate Injection administration to lessen the risk of bradycardia [ see Dosage and Administration ( 2.4 ) ]. (notice Néostigmine, Mises en garde et précautions)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (notice Olicéridine, Interactions médicamenteuses)

Anticholinergic Drugs Use of anticholinergic drugs after administration of BOTOX may potentiate systemic anticholinergic effects. (notice OnabotulinumtoxinA, Interactions médicamenteuses)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (notice Oxycodone, Interactions médicamenteuses)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may result in increased risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (notice Oxycodone et paracétamol, Interactions médicamenteuses)

Examples: cyclobenzaprine, metaxalone Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (notice Oxymorphone, Interactions médicamenteuses)

Anticholinergic Drugs The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (notice Paracétamol et codéine, Interactions médicamenteuses)

Monitor patients for signs of diminished diuresis and/or effects on blood pressure and increase the dosage of the diuretic as needed Anticholinergic Drugs The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (notice Pentazocine et naloxone, Interactions médicamenteuses)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever and primary central nervous system (CNS) pathology. (notice Perphénazine, Mises en garde)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (notice Péthidine, Interactions médicamenteuses)

These effects should be considered when anticholinergic properties may be contributing to the therapeutic effect of concomitant medication (e.g., atropine, inhaled ipratropium). (notice Pilocarpine, Interactions médicamenteuses)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever and primary central nervous system (CNS) pathology. (notice Pimozide, Mises en garde)

Anticholinergic drugs administered concurrently with PA may produce additive antivagal effects on A-V nodal conduction, although this is not as well documented for PA as for quinidine. (notice Procaïnamide, Interactions médicamenteuses)

The intravenous administration of anticholinergic agents (e.g., atropine or glycopyrrolate) should be considered to modify potential increases in vagal tone due to concomitant agents (e.g., succinylcholine) or surgical stimuli. (notice Propofol, Mises en garde et précautions)

Use with caution in persons with increased risk of anticholinergic reactions, such as persons with bronchial asthma, chronic obstructive pulmonary disease, bradycardia, cardiac arrhythmias, beta blocker treatment (increased risk of anticholinergic reactions). (notice Pyridostigmine, Mises en garde et précautions)

• Anticholinergic (antimuscarinic) Effects: Use with caution with other anticholinergic drugs and in patients with urinary retention, prostatic hypertrophy, or constipation (5.20) (notice Quétiapine, Mises en garde et précautions)

Bronchodilator: theophylline ↓ theophylline Increased dosage of theophylline may be required; therapeutic monitoring should be considered. (notice Ritonavir, Interactions médicamenteuses)

Consider having an anticholinergic and epinephrine available when administering sevoflurane for induction in this patient population. (notice Sévoflurane, Mises en garde)

Monitor for hemodynamic changes and administer anticholinergic agents such as atropine if clinically significant bradycardia is observed. (notice Sugammadex, Mises en garde et précautions)

Pretreatment with anticholinergic agents (e.g., atropine) may reduce the occurrence of bradyarrhythmias. (notice Suxaméthonium, Mises en garde et précautions)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (notice Tapentadol, Interactions médicamenteuses)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (notice Tétrabénazine, Mises en garde et précautions)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever and primary central nervous system (CNS) pathology. (notice Tiotixène, Mises en garde)

Caution should be used when topiramate extended-release capsules are prescribed with other drugs that predispose patients to heat-related disorders; these drugs include, but are not limited to, other carbonic anhydrase inhibitors and drugs with anticholinergic activity. (notice Topiramate, Mises en garde et précautions)

Aminoglycosides or other agents interfering with neuromuscular transmission Anticholinergic drugs Botulinum neurotoxin products Muscle relaxants Aminoglycoside antibiotics, anticholinergic agents, or any other agents that interfere with neuromuscular transmission may potentiate the effect of DAXXIFY; co-administer only with caution and close observation. (notice Toxine botulinique de type A, Interactions médicamenteuses)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (notice Tramadol, Interactions médicamenteuses)

Anticholinergic Drugs Clinical Impact: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. (notice Tramadol et paracétamol, Interactions médicamenteuses)

Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever and primary central nervous system (CNS) pathology. (notice Trifluopérazine, Mises en garde)

The recent use of other drugs that cause CNS depression or EPS symptoms (e.g., alcohol, sedatives, hypnotics, opiates, anxiolytics, antipsychotics, and anticholinergics) may also increase the risk for these serious CNS reactions [see Warnings and Precautions ( 5.1 , 5.5 )] . (notice Triméthobenzamide, Mises en garde et précautions)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system pathology. (notice Valbénazine, Mises en garde et précautions)

Urinary Retention : Monitor for urinary retention, especially in patients with bladder outlet obstruction and also in patients taking muscarinic antagonist medications for OAB, in whom the risk of urinary retention may be greater. (notice Vibégron, Mises en garde et précautions)

If a decision is made to prescribe RELENZA for such a patient, this should be done only under conditions of careful monitoring of respiratory function, close observation, and appropriate supportive care, including availability of fast‑acting bronchodilators. (notice Zanamivir, Mises en garde et précautions)

Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever, and primary central nervous system (CNS) pathology. (notice Ziprasidone, Mises en garde et précautions)

Caution should be used when ZONISADE is prescribed with other drugs that predispose patients to heat-related disorders; these drugs include, but are not limited to, carbonic anhydrase inhibitors and drugs with anticholinergic activity. (notice Zonisamide, Mises en garde et précautions)

A bronchodilator, such as theophylline or a β2-stimulant, should be made available in advance with instructions concerning its use. (notice Acébutolol, Mises en garde)

Use for Maintenance Treatment Only ATROVENT HFA is a bronchodilator for the maintenance treatment of bronchospasm associated with COPD and is not indicated for the initial treatment of acute episodes of bronchospasm where rescue therapy is required for rapid response. (notice Ipratropium, Mises en garde et précautions)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

Use for Maintenance Treatment Only ATROVENT HFA is a bronchodilator for the maintenance treatment of bronchospasm associated with COPD and is not indicated for the initial treatment of acute episodes of bronchospasm where rescue therapy is required for rapid response. (notice Ipratropium, Mises en garde et précautions)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (notice Bévacizumab, Mises en garde et précautions)

A beta 2 agonist (bronchodilator) should be made available. (notice Bisoprolol, Mises en garde)

A beta 2 agonist (bronchodilator) should be made available. (notice Bisoprolol et hydrochlorothiazide, Mises en garde)

Use for Maintenance Treatment Only ATROVENT HFA is a bronchodilator for the maintenance treatment of bronchospasm associated with COPD and is not indicated for the initial treatment of acute episodes of bronchospasm where rescue therapy is required for rapid response. (notice Ipratropium, Mises en garde et précautions)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

Cevimeline might interfere with desirable antimuscarinic effects of drugs used concomitantly. (notice Céviméline, Interactions médicamenteuses)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the C max of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to… (notice Clonazépam, Interactions médicamenteuses)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

Cholinesterase inhibitors have the potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Donépézil, Interactions médicamenteuses)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

Flumazenil is not recommended in cases of serious cyclic antidepressant poisoning, as manifested by motor abnormalities (twitching, rigidity, focal seizure), dysrhythmia (wide QRS, ventricular dysrhythmia, heart block), anticholinergic signs (mydriasis, dry mucosa, hypoperistalsis), and cardiovascular collapse at presentation. (notice Flumazénil, Mises en garde)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

Use for Maintenance Treatment Only ATROVENT HFA is a bronchodilator for the maintenance treatment of bronchospasm associated with COPD and is not indicated for the initial treatment of acute episodes of bronchospasm where rescue therapy is required for rapid response. (notice Ipratropium, Mises en garde et précautions)

Use for Maintenance Treatment Only ATROVENT HFA is a bronchodilator for the maintenance treatment of bronchospasm associated with COPD and is not indicated for the initial treatment of acute episodes of bronchospasm where rescue therapy is required for rapid response. (notice Ipratropium, Mises en garde et précautions)

Potential to interfere with the activity of anticholinergic medications ( 7.1 ) (notice Galantamine, Interactions médicamenteuses)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

In a study of patients with asthma whose bronchodilators were temporarily withheld for assessment, bronchoconstriction and wheezing following AFREZZA dosing was reported in 29% (5/17) and 0% (0/13) of patients with and without a diagnosis of asthma, respectively. (notice Insuline rapide (humaine), Mises en garde et précautions)

Use for Maintenance Treatment Only ATROVENT HFA is a bronchodilator for the maintenance treatment of bronchospasm associated with COPD and is not indicated for the initial treatment of acute episodes of bronchospasm where rescue therapy is required for rapid response. (notice Ipratropium, Mises en garde et précautions)

Beta blockers antagonize the bronchodilator effect of beta-receptor agonists. (notice Labétalol, Interactions médicamenteuses)

Use for Maintenance Treatment Only ATROVENT HFA is a bronchodilator for the maintenance treatment of bronchospasm associated with COPD and is not indicated for the initial treatment of acute episodes of bronchospasm where rescue therapy is required for rapid response. (notice Ipratropium, Mises en garde et précautions)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic drugs may contribute to an elevation in core body temperature. (notice Lumatépérone, Mises en garde et précautions)

Appropriate care is advised when prescribing LATUDA for patients who will be experiencing conditions that may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to dehydration. (notice Lurasidone, Mises en garde et précautions)

NAMZARIC may interfere with anticholinergic medications. (notice Mémantine et donépézil, Interactions médicamenteuses)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

Appropriate care is advised when prescribing ERZOFRI to patients who will be experiencing conditions which may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to dehydration. (notice Palipéridone, Mises en garde et précautions)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

It is responsive to ephedrine or anticholinergic drugs ( 5.8 ) (notice Rémifentanil, Mises en garde et précautions)

Institute medical management (e.g., glucocorticoids, epinephrine, bronchodilators, or oxygen) for infusion-related reactions as needed. (notice Rituximab, Mises en garde et précautions)

Use for Maintenance Treatment Only ATROVENT HFA is a bronchodilator for the maintenance treatment of bronchospasm associated with COPD and is not indicated for the initial treatment of acute episodes of bronchospasm where rescue therapy is required for rapid response. (notice Ipratropium, Mises en garde et précautions)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

Use for Maintenance Treatment Only ATROVENT HFA is a bronchodilator for the maintenance treatment of bronchospasm associated with COPD and is not indicated for the initial treatment of acute episodes of bronchospasm where rescue therapy is required for rapid response. (notice Ipratropium, Mises en garde et précautions)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

It is difficult to determine if Tolcapone tablets played a role in the pathogenesis of these events because these patients received several concomitant medications affecting the central nervous system such as monoaminergic (i.e., MAO-I, tricyclic and selective serotonin reuptake inhibitors) and anticholinergic agents. (notice Tolcapone, Précautions)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

Commonly Administered Drugs: Population analysis showed that commonly administered drugs (e.g., selegiline, amantadine, tricyclic antidepressants, benzodiazepines, ibuprofen, thiazides, antihistamines, anticholinergics) did not affect the clearance of ropinirole. (notice Ropinirole, Interactions médicamenteuses)